Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology.
Transformants with stable expression of a series of human cytochrome P450 (CYP) subtypes in the human hepatic cell line, HepG2, were established. These transformants are designated Hepc/1A1.4, Hepc/1A2.9, Hepc/2A6L.14, Hepc/2B6.68, Hepc/2C8.46, Hepc/2C9.1, Hepc/2C19.12, Hepc/2D6.39, Hepc/2E1.3-8 and Hepc/3A4.2-30, which stably expressed human CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4, respectively. The expression of the CYP subtypes in the transformants was confirmed by both determination of enzyme activities and the reverse transcriptase polymerase chain reaction (RT-PCR) procedure. The apparent K(m) values of the expressed CYP subtypes for their specific substrates were close to those of human liver microsomes. In addition to their CYP activities, these transformants retained glucuronide- and sulfate-conjugating activities. Furthermore, the activities of CYP2C9, CYP2D6 and CYP3A4 were inhibited by their specific inhibitors. The cytotoxicity of acetaminophen (APAP), cyclophosphamide (CPA) and benz[a]anthracene (BA) were analyzed by CYP-expressing transformants. The cytotoxicity depended on the expression of CYP subtypes and increased in a dose-dependent manner. These results show the metabolic activation of APAP, CPA and BA by the specific CYP subtypes expressed in the transformants and demonstrate the usefulness of these transformants for in vitro metabolic and toxicological studies in human liver.
Yoshitomi
S
S
Drug Analysis and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division, Takeda Chemical Industries Ltd, 2-17-85 Juso-Honmachi, Yodogawa-ku, 532-8686, Osaka, Japan. Yoshitomi_Sumie@takeda.co.jp
Ikemoto
K
K
Takahashi
J
J
Miki
H
H
Namba
M
M
Asahi
S
S
D000082:Acetaminophen / Q000633:toxicity; D001551:Benz(a)Anthracenes / Q000633:toxicity; D002384:Catalysis; D002460:Cell Line; D002461:Cell Line, Transformed / Q000201:enzymology* / Q000473:pathology; D003520:Cyclophosphamide / Q000633:toxicity; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors; D004847:Epithelial Cells / Q000201:enzymology; D015870:Gene Expression; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D007700:Kinetics; D008099:Liver; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013379:Substrate Specificity; D014116:Toxicology / Q000379:methods*; D014162:Transfection; D015262:Xenobiotics / Q000633:toxicity
D001551:Benz(a)Anthracenes; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D012333:RNA, Messenger; D015262:Xenobiotics; D000082:Acetaminophen; D003520:Cyclophosphamide; D003577:Cytochrome P-450 Enzyme System; C030935:benz(a)anthracene